Michael Charles, MD
Surgical Critical Care · Tulsa, OKNPI 1942293097
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 46.7% of the total. Reporting peaked in 2024 at $4,399 and has fallen 93.0% since, to $306 in 2025.
Across 67 payments — averaging $132.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$4K
- AbbVie$3K
- KCI USA, Inc.$764
- Medtronic$167
- AstraZeneca$162
- Smith+Nephew$108
- plus $275 from 5 others
Across 79 payments — averaging $2993.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$62K
- AstraZeneca$44K
- CSL Behring$43K
- Mitsubishi Tanabe Pharma Development America, Inc.$36K
- Covidien LP$28K
- Tanabe Pharma America, Inc.$24K
What the payments were for
- Travel & lodging$5,05257%
- Food & beverage$3,68342%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 25 | $4,129 |
| AbbVie(2 entities) | 26 | $3,240 |
| KCI USA, Inc. | 6 | $764 |
| Medtronic | 1 | $167 |
| AstraZeneca | 2 | $162 |
| Smith+Nephew | 1 | $108 |
| Medline Industries LP | 2 | $97 |
| CLR Medical, Inc. | 1 | $75 |
| Intuitive Surgical | 1 | $65 |
| Shire North American Group Inc | 1 | $23 |
| Avanos Medical | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE SALINE-FILLED BREAST IMPLANTS$4,526
- GORE BIO-A Tissue Reinforcement$3,308
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$2,388
- REVOLVE$2,263
- PREVENA$654
- ABTHERA$654
- VAC VERAFLO$654
- TRANSORB$167
- VAC VIA$154
- STRATTICE$124
- ANDEXXA$122
- Santyl$108
- REGRANEX$108
- Oasis$108
How this compares
Too few surgical critical care providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 26 | $46 |
Paid to pharmacies, not to this prescriber.
Other surgical critical care in Tulsa
- Nathan PowellTulsa$22K
- Aaron AlvaradoTulsa$7K
- Kerri-Anne VlamingTulsa$3K
- John Marc ShellenbergerTulsa$3K
- Debra VanzandtTulsa$2K
- Jared SheppardTulsa$1K
- Alex OlsenTulsa$1K
- Robert GoodwinTulsa$1K
- Joseph FugaroTulsa$912
- Keith ChamplinTulsa$740
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.